The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Ammonium Hydroxide results in increased expression of and results in increased activity of HMOX1 protein Ammonium Hydroxide results in increased expression of HMOX1 mRNA
Augmentin cotreated with ethanol increases expression of Slc1a2 in prefrontal cortex and nucleus accumbens Augmentin inhibits the reaction [ethanol decreases expression of Slc1a2 protein in nucleus accumbens] Augmentin inhibits the reaction [ethanol decreases expression of Slc1a2 protein in prefrontal cortex]
Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA Augmentin inhibits the reaction [ethanol decreases expression of Slc7a11 protein in nucleus accumbens and prefrontal cortex] Augmentin cotreated with ethanol increases expression of Slc7a11 in prefrontal cortex and nucleus accumbens
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of BAX protein] Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of DDC mRNA] Carbidopa binds to and results in decreased activity of DDC protein
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of IL1B protein] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of TNF protein] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of TNF protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of TNF protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 protein]
[Cilazapril co-treated with Losartan] promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Cilazapril promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]
[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Cilazapril inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]
[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Cilazapril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]
Deuterium Oxide results in decreased phosphorylation of AKT1 protein Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT1 protein]
Deuterium Oxide results in decreased phosphorylation of AKT2 protein Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT2 protein]
Deuterium Oxide results in decreased phosphorylation of AKT3 protein Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT3 protein]
Deuterium Oxide results in increased expression of BECN1 protein Acetylcysteine inhibits the reaction [Deuterium Oxide results in increased expression of BECN1 protein]
Acetylcysteine inhibits the reaction [Deuterium Oxide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Deuterium Oxide results in increased expression of and results in increased lipidation of MAP1LC3B protein
Deuterium Oxide results in decreased phosphorylation of MTOR protein Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of MTOR protein]
ABCC1 protein affects the susceptibility to Antimony Potassium Tartrate ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate ABCC1 protein results in increased secretion of Antimony Potassium Tartrate [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate; Glutathione affects the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]
Antimony Potassium Tartrate results in increased expression of ABCC2 mRNA; Antimony Potassium Tartrate results in increased expression of ABCC2 protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC2 mRNA
Antimony Potassium Tartrate results in increased expression of AKR1B10 mRNA [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA
Antimony Potassium Tartrate results in increased expression of AKR1C3 mRNA; Antimony Potassium Tartrate results in increased expression of AKR1C3 protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1C3 mRNA
666-15 compound promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein
BECN1 protein affects the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 protein]; BECN1 protein affects the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL protein]
Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]; Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]
666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein; pyrazolanthrone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]
Antimony Potassium Tartrate results in decreased expression of DSC1 mRNA [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA]
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]
Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA] Antimony Potassium Tartrate results in decreased expression of DUOX1 mRNA
Antimony Potassium Tartrate results in decreased expression of FLG mRNA 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]
Antimony Potassium Tartrate results in increased expression of FTH1 mRNA; Antimony Potassium Tartrate results in increased expression of FTH1 protein 3-methyladenine inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 protein; FTH1 protein inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein] [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTH1 mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] promotes the reaction [Cycloheximide results in decreased expression of FTH1 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 protein; BECN1 protein affects the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 protein]; Chloroquine inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 protein]; FTH1 protein inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein]; NCOA4 protein affects the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 protein]
Antimony Potassium Tartrate results in increased expression of FTL mRNA 3-methyladenine inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTL mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] promotes the reaction [Cycloheximide results in decreased expression of FTL protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL protein; BECN1 protein affects the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL protein]; Chloroquine inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL protein]; NCOA4 protein affects the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL protein]
Antimony Potassium Tartrate results in increased expression of GCLC mRNA; Antimony Potassium Tartrate results in increased expression of GCLC protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLC mRNA
Antimony Potassium Tartrate results in increased expression of GCLM mRNA [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLM mRNA
666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein; ferrostatin-1 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein]; FTH1 protein inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein] [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein; Deferoxamine inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein]; ferrostatin-1 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein]; FTH1 protein inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of GPX4 protein]
Antimony Potassium Tartrate results in increased expression of HMOX1 mRNA; Antimony Potassium Tartrate results in increased expression of HMOX1 protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HMOX1 mRNA
Antimony Potassium Tartrate results in decreased expression of IVL mRNA; Antimony Potassium Tartrate results in decreased expression of IVL protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IVL mRNA
Antimony Potassium Tartrate results in increased expression of KLK3 mRNA; Antimony Potassium Tartrate results in increased expression of KLK3 protein bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of KLK3 mRNA]
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]
Antimony Potassium Tartrate results in decreased expression of KRT10 mRNA; Antimony Potassium Tartrate results in decreased expression of KRT10 protein 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased lipidation of MAP1LC3B protein; Chloroquine promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased lipidation of MAP1LC3B protein]
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK1 protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK1 protein
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK3 protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK3 protein
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate MYCN protein results in decreased susceptibility to Antimony Potassium Tartrate
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NCOA4 protein; NCOA4 protein affects the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTH1 protein]; NCOA4 protein affects the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of FTL protein]
Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA; Antimony Potassium Tartrate results in increased expression of NKX3-1 protein bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA]
666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]
Antimony Potassium Tartrate results in increased expression of NQO1 mRNA; Antimony Potassium Tartrate results in increased expression of NQO1 protein [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NQO1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]
Antimony Potassium Tartrate affects the localization of PML protein Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein] Antimony Potassium Tartrate results in increased degradation of PML protein mutant form
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of PTGS2 protein; Deferoxamine inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of PTGS2 protein]; ferrostatin-1 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of PTGS2 protein]
3-methyladenine inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of RBFOX3 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of RBFOX3 protein
Antimony Potassium Tartrate results in decreased expression of S100A8 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A8 protein
Antimony Potassium Tartrate results in decreased expression of S100A9 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A9 protein
Antimony Potassium Tartrate results in decreased expression of SPRR1A mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1A protein
Antimony Potassium Tartrate results in decreased expression of SPRR1B mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1B protein
Antimony Potassium Tartrate results in decreased expression of SPRR3 mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of STAT1 mRNA
Antimony Potassium Tartrate affects the localization of SUMO1 protein Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]
Antimony Potassium Tartrate results in increased expression of TXNRD1 mRNA [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXNRD1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of UGT1A6 mRNA Antimony Potassium Tartrate results in increased expression of UGT1A6 mRNA
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA]
AQP1 protein results in increased transport of Water Mercuric Chloride inhibits the reaction [AQP1 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP1 protein results in increased transport of Water]
Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]
Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]; Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]] Water deficiency results in increased expression of AQP3 mRNA; Water deficiency results in increased expression of AQP3 protein Copper Sulfate inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]
AQP4 protein results in increased transport of Water AQP4 protein results in increased susceptibility to Water Water deficiency results in increased expression of AQP4 mRNA AQP4 protein affects the transport of Water
Copper affects the reaction [AQP8 protein affects the transport of Water]; Mercury affects the reaction [AQP8 protein affects the transport of Water] AQP8 protein results in increased transport of Water Mercuric Chloride inhibits the reaction [AQP8 protein results in increased transport of Water]
CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; Mercuric Chloride inhibits the reaction [AQP9 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of AVP protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein]
[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA; [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which affects the expression of CASP1 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA]
[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein]
[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein] [[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of CAT mRNA
[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein] [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA]
1-Methyl-3-isobutylxanthine promotes the reaction [CFTR protein affects the transport of Water]; CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CFTR protein affects the transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 protein
[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein]
[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA; AM 251 inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein]
Water deficiency results in increased expression of HMOX1 protein [[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of HMOX1 mRNA
[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein] [[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA; arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA]
[Glucose results in increased activity of SLC12A1 protein] which results in increased import of Water; [Mannitol results in increased activity of SLC12A1 protein] which results in increased import of Water SLC12A1 protein results in increased import of Water
Water deficiency results in increased expression of SOD2 protein [[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of SOD2 mRNA
[Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein
TAC1 protein alternative form inhibits the reaction [Cholera Toxin results in increased secretion of Water]; TAC1 protein inhibits the reaction [Cholera Toxin results in increased secretion of Water]
[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein] [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]
Enalaprilat results in decreased expression of AGT protein modified form Enalaprilat inhibits the reaction [Glucose results in increased expression of AGT protein]
bradykinin, Lys-Leu(8)-desArg(9)- inhibits the reaction [Enalaprilat results in increased activity of BDKRB1 protein]; Zinc affects the reaction [Enalaprilat results in increased activity of BDKRB1 protein]
Enalaprilat results in decreased expression of FN1 mRNA; Enalaprilat results in decreased expression of FN1 protein Enalaprilat inhibits the reaction [Glucose results in increased expression of FN1 mRNA]
Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD2 mRNA]
Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 protein]
gadodiamide results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]
gadodiamide results in increased expression of CCL2 mRNA gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein gadodiamide results in increased secretion of CCL2 protein
gadodiamide results in increased expression of CXCL10 mRNA gadodiamide results in increased expression of CXCL10 protein gadodiamide results in increased secretion of CXCL10 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein] gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein
gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein]
Lisinopril results in increased expression of ACE2 mRNA ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)] Lisinopril results in increased activity of ACE2 protein
bisphenol A diglycidyl ether inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein] Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]
Lisinopril results in decreased expression of AGT protein Lisinopril results in increased expression of AGT mRNA AGT gene alternative form affects the susceptibility to Lisinopril Lisinopril results in increased secretion of AGT protein alternative form Lisinopril results in decreased secretion of AGT protein [Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA Lisinopril affects the metabolism of AGT protein [[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]
Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein]
[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]
bisphenol A diglycidyl ether inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]
Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein]
Lisinopril results in increased expression of REN protein [Lisinopril co-treated with Losartan] results in increased expression of REN mRNA Lisinopril results in increased expression of REN mRNA
Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein]
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein]
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein] [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]
NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide]
mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 mRNA]; mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 protein]
potassium hydroxide results in decreased expression of and affects the localization of HSPB1 protein potassium hydroxide results in increased expression of HSPB1 mRNA
royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein]
royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein]
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Tartrazine results in decreased activity of CAT protein] royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]
Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein] royal jelly results in increased activity of ESR1 protein
Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein]
royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA] royal jelly results in decreased expression of MYC mRNA royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA]
Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1A1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]
Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]
Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein]
[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]
Sodium Hydroxide results in increased expression of CASP3 mRNA lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of CASP3 mRNA]
Sodium Hydroxide results in increased expression of COL1A2 protein lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of COL1A2 protein]
Sodium Hydroxide results in increased expression of FN1 protein lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of FN1 protein]
Sodium Hydroxide results in increased expression of JUN mRNA lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of JUN mRNA]
Sodium Hydroxide results in increased expression of MMP9 mRNA lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of MMP9 mRNA]
ABCB1 protein affects the export of Tacrolimus Tacrolimus results in decreased activity of ABCB1 protein [Tacrolimus binds to ABCB1 protein] inhibits the reaction [azidoprazosin binds to ABCB1 protein]; [Tacrolimus results in decreased activity of ABCB1 protein] which results in decreased export of Dexamethasone; Verapamil affects the reaction [ABCB1 protein results in increased export of Tacrolimus] ABCB1 gene SNP results in increased susceptibility to Tacrolimus ABCB1 protein affects the susceptibility to Tacrolimus
[Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]
Tacrolimus inhibits the reaction [Ammonium Chloride results in decreased phosphorylation of BAD protein] Tacrolimus inhibits the reaction [Rotenone results in decreased phosphorylation of BAD protein]
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein] Tacrolimus results in increased expression of BAX protein [Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BAX protein
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein] Tacrolimus results in decreased expression of BCL2 protein [Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BCL2 protein Tacrolimus results in increased expression of BCL2 protein
Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]; Tacrolimus promotes the reaction [U 0126 inhibits the reaction [decamethrin results in increased expression of BDNF exon]]; U 0126 promotes the reaction [Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]]
Ramipril inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]; valsartan inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]
Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein] Tacrolimus results in increased cleavage of CASP3 protein Tacrolimus results in increased activity of CASP3 protein MK0626 inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; NGF protein inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [3-nitropropionic acid results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Oxygen deficiency results in increased activity of CASP3 protein] Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [S-Nitrosoglutathione results in increased activity of CASP3 protein]
Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP8 protein] Tacrolimus results in increased expression of CASP8 protein
Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP9 protein] Tacrolimus results in increased expression of CASP9 protein
pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA] Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein] 7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; 7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]
Tacrolimus results in decreased expression of CCL5 mRNA Tacrolimus results in increased expression of CCL5 mRNA 7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]
Tacrolimus inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; Tacrolimus inhibits the reaction [Paraquat results in increased secretion of CCN2 protein]
Tacrolimus results in decreased expression of CSF2 protein Tacrolimus results in increased expression of CSF2 mRNA Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]]; Tacrolimus inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CSF2 protein]
Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CTSL protein] Tacrolimus results in increased expression of CTSL mRNA
CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]
CYP3A4 protein results in increased metabolism of Tacrolimus CYP3A4 protein affects the metabolism of Tacrolimus CYP3A4 protein results in decreased methylation of Tacrolimus Metronidazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Tacrolimus]
CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus] CYP3A5 protein results in decreased methylation of Tacrolimus CYP3A5 gene polymorphism affects the metabolism of Tacrolimus; CYP3A5 gene SNP affects the metabolism of Tacrolimus; CYP3A5 protein affects the metabolism of Tacrolimus; CYP3A5 protein polymorphism affects the metabolism of Tacrolimus CYP3A5 gene affects the susceptibility to Tacrolimus; CYP3A5 polymorphism affects the susceptibility to Tacrolimus
salubrinal promotes the reaction [Tacrolimus results in increased expression of DDIT3 protein] Tacrolimus results in increased expression of DDIT3 mRNA
PINK1 protein affects the reaction [Tacrolimus results in increased phosphorylation of DNM1L protein] Tacrolimus inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]
Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP9 protein]
[Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein]; [Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]] Tacrolimus results in increased expression of FKBP1A protein
[GSK3A protein co-treated with GSK3B protein] affects the reaction [Tacrolimus results in increased expression of SNAI1 protein] Tacrolimus results in increased phosphorylation of GSK3A protein
[GSK3A protein co-treated with GSK3B protein] affects the reaction [Tacrolimus results in increased expression of SNAI1 protein] Tacrolimus results in increased phosphorylation of GSK3B protein
Tacrolimus results in increased expression of HMOX1 mRNA; Tacrolimus results in increased expression of HMOX1 protein Tacrolimus results in decreased expression of HMOX1 protein MK0626 inhibits the reaction [Tacrolimus results in decreased expression of HMOX1 protein]
Tacrolimus inhibits the reaction [Acrylamide results in decreased expression of HSPA8 protein] Tacrolimus results in increased expression of HSPA8 protein
Tacrolimus results in decreased expression of ICAM1; Tacrolimus results in decreased expression of ICAM1 protein Tacrolimus results in increased expression of ICAM1 mRNA
[Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IFNG protein]; Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of IFNG protein]; Tacrolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IFNG mRNA] Tacrolimus results in decreased expression of IFNG protein Tacrolimus results in decreased expression of IFNG mRNA; Tacrolimus results in decreased expression of IFNG protein [Tacrolimus co-treated with TAK 779] results in decreased expression of IFNG protein Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TRP53 protein] Tacrolimus results in decreased secretion of IFNG protein
[Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [CD2 protein results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of IL2 protein]; Tacrolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 mRNA]; Tacrolimus inhibits the reaction [Zinc Sulfate inhibits the reaction [Mitogens results in increased expression of IL2 mRNA]] Tacrolimus results in decreased expression of IL2 mRNA; Tacrolimus results in decreased expression of IL2 protein Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of IL2 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]
Tacrolimus results in decreased expression of IL3 protein Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL3 protein]]; Tacrolimus inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL3 protein]
Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL4 protein] Tacrolimus results in decreased expression of IL4 mRNA; Tacrolimus results in decreased expression of IL4 protein Tacrolimus inhibits the reaction [bisphenol A promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [bisphenol A results in increased expression of IL4 protein]; Tacrolimus inhibits the reaction [nonylphenol promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [nonylphenol results in increased expression of IL4 protein]
Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL5 protein] Tacrolimus results in decreased expression of IL5 mRNA; Tacrolimus results in decreased expression of IL5 protein
[Tacrolimus co-treated with quinapril] results in decreased expression of IL6 protein; [Tacrolimus co-treated with quinapril] results in increased expression of IL6 protein; [Tacrolimus co-treated with Valsartan] results in decreased expression of IL6 protein; [Tacrolimus co-treated with Valsartan] results in increased expression of IL6 protein Tacrolimus results in increased expression of IL6 mRNA parthenolide inhibits the reaction [Tacrolimus results in increased expression of IL6 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of IL6 mRNA] Tacrolimus results in increased expression of IL6 protein Tacrolimus results in decreased expression of IL6 protein
Tacrolimus results in decreased activity of MAPK8 protein Tacrolimus inhibits the reaction [Oxygen deficiency results in increased activity of MAPK8 protein]
Tacrolimus inhibits the reaction [bisphenol A promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [nonylphenol promotes the reaction [NFATC3 protein binds to IL4 promoter]]; Tacrolimus inhibits the reaction [Thapsigargin affects the localization of and results in increased activity of NFATC3 protein]
Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [Phenylephrine results in increased localization of NFATC4 protein]
Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of NFKB1 protein] Tacrolimus results in increased expression of NFKB1 mRNA
Tacrolimus results in decreased degradation of NFKBIA protein Tacrolimus results in increased phosphorylation of NFKBIA protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased phosphorylation of NFKBIA protein]
NGF protein inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [NGF protein results in increased expression of SERPINE1 mRNA]; Tacrolimus inhibits the reaction [NGF protein results in increased expression of SERPINE1 protein]
Tacrolimus inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased expression of NOS2 protein]; Tacrolimus inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] Tacrolimus inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Tacrolimus inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]
Tacrolimus results in increased expression of NOS3 mRNA Tacrolimus results in decreased expression of NOS3 mRNA Tacrolimus results in decreased activity of NOS3 protein
Tacrolimus inhibits the reaction [NPR1 protein affects the expression of FN1 mRNA]; Tacrolimus inhibits the reaction [NPR1 protein affects the expression of NPPA mRNA]; Tacrolimus inhibits the reaction [NPR1 protein affects the expression of NPPB mRNA]
Tacrolimus inhibits the reaction [NR3C1 protein binds to FKBP5 protein]; Tacrolimus promotes the reaction [Dexamethasone binds to NR3C1 protein]; Tacrolimus promotes the reaction [NR3C1 protein binds to PPP5C protein] Tacrolimus results in increased activity of NR3C1 protein
Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein]; Tacrolimus affects the reaction [Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein]]
Tacrolimus inhibits the reaction [bisperoxovanadium results in increased expression of PTGS2 mRNA] Tacrolimus results in increased expression of PTGS2 mRNA
[Tacrolimus co-treated with Thapsigargin] affects the localization of and results in increased activity of RELA protein; Tacrolimus affects the localization of and results in increased activity of RELA protein; Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of RELA protein]; Tacrolimus results in increased phosphorylation of and affects the localization of RELA protein
nilvadipine inhibits the reaction [Tacrolimus results in increased expression of REN protein] Tacrolimus results in increased expression of REN mRNA; Tacrolimus results in increased expression of REN protein Tacrolimus results in decreased activity of REN protein
Tacrolimus results in increased expression of SERPINE1 mRNA Tacrolimus inhibits the reaction [Mercuric Chloride results in increased expression of SERPINE1 protein]; Tacrolimus inhibits the reaction [NGF protein results in increased expression of SERPINE1 mRNA]; Tacrolimus inhibits the reaction [NGF protein results in increased expression of SERPINE1 protein]
SLC12A3 protein affects the susceptibility to Tacrolimus Tacrolimus results in decreased expression of SLC12A3 mRNA; Tacrolimus results in decreased expression of SLC12A3 protein Tacrolimus results in increased phosphorylation of SLC12A3 protein
Tacrolimus inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of SMAD3 protein]; Tacrolimus inhibits the reaction [Paraquat results in increased expression of SMAD3 mRNA]
Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]; Tacrolimus inhibits the reaction [SMAD7 protein binds to SMURF1 protein] Tacrolimus promotes the reaction [Paraquat results in increased expression of and results in increased secretion of SMAD7 protein]; Tacrolimus promotes the reaction [Paraquat results in increased expression of SMAD7 mRNA]
Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]; Tacrolimus inhibits the reaction [SMAD7 protein binds to SMURF1 protein]
Tacrolimus results in increased expression of SNAI1 protein [GSK3A protein co-treated with GSK3B protein] affects the reaction [Tacrolimus results in increased expression of SNAI1 protein]
SOD2 protein results in increased susceptibility to Tacrolimus Tacrolimus results in decreased expression of SOD2 protein MK0626 inhibits the reaction [Tacrolimus results in decreased expression of SOD2 protein]
[Cyclosporine co-treated with Tacrolimus] inhibits the reaction [4-(4-fluorophenyl)sulfonyl-5-methylthio-2-phenyloxazole affects the localization of TFEB protein]
Ramipril inhibits the reaction [Tacrolimus results in increased expression of TGFB1 mRNA] Tacrolimus results in increased expression of TGFB1 mRNA; Tacrolimus results in increased expression of TGFB1 protein Tacrolimus results in decreased expression of TGFB1 mRNA [Tacrolimus co-treated with Quinapril] results in increased expression of TGFB1 protein; [Tacrolimus co-treated with Valsartan] results in increased expression of TGFB1 protein; pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of TGFB1 mRNA]; Ramipril inhibits the reaction [Tacrolimus results in increased expression of TGFB1 protein]; Tacrolimus inhibits the reaction [Mercuric Chloride results in increased expression of TGFB1 protein]; Tacrolimus inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of TGFB1 protein]; Tacrolimus inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]; Valsartan inhibits the reaction [Tacrolimus results in increased expression of TGFB1 protein]
pirfenidone promotes the reaction [Tacrolimus results in decreased expression of TIMP1 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of TIMP1 mRNA]
Tacrolimus inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides]; Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF protein]; Tacrolimus inhibits the reaction [Dieldrin results in increased expression of TNF mRNA]; Tacrolimus inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of TNF protein]; Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; Tacrolimus inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] Tacrolimus results in increased expression of TNF mRNA Tacrolimus inhibits the reaction [Indomethacin results in increased expression of TNF mRNA] [Tacrolimus co-treated with Thapsigargin] results in increased expression of TNF protein Tacrolimus results in decreased expression of TNF mRNA; Tacrolimus results in decreased expression of TNF protein Tacrolimus results in decreased secretion of TNF protein
Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]; Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]
Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TRP53 protein]
Tacrolimus results in increased phosphorylation of and affects the activity of TRPV1 protein Tacrolimus affects the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]
Tacrolimus results in increased expression of and affects the localization of XBP1 protein modified form Tacrolimus results in increased expression of XBP1 mRNA
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA]
AQP1 protein results in increased transport of Water Mercuric Chloride inhibits the reaction [AQP1 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP1 protein results in increased transport of Water]
Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]
Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]; Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]] Water deficiency results in increased expression of AQP3 mRNA; Water deficiency results in increased expression of AQP3 protein Copper Sulfate inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]
AQP4 protein results in increased transport of Water AQP4 protein results in increased susceptibility to Water Water deficiency results in increased expression of AQP4 mRNA AQP4 protein affects the transport of Water
Copper affects the reaction [AQP8 protein affects the transport of Water]; Mercury affects the reaction [AQP8 protein affects the transport of Water] AQP8 protein results in increased transport of Water Mercuric Chloride inhibits the reaction [AQP8 protein results in increased transport of Water]
CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; Mercuric Chloride inhibits the reaction [AQP9 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of AVP protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein]
[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA; [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which affects the expression of CASP1 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA]
[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein]
[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein] [[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of CAT mRNA
[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein] [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA]
1-Methyl-3-isobutylxanthine promotes the reaction [CFTR protein affects the transport of Water]; CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CFTR protein affects the transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 protein
[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein]
[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA; AM 251 inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein]
Water deficiency results in increased expression of HMOX1 protein [[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of HMOX1 mRNA
[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein] [[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA; arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA]
[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA]
[Glucose results in increased activity of SLC12A1 protein] which results in increased import of Water; [Mannitol results in increased activity of SLC12A1 protein] which results in increased import of Water SLC12A1 protein results in increased import of Water
Water deficiency results in increased expression of SOD2 protein [[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of SOD2 mRNA
[Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein
TAC1 protein alternative form inhibits the reaction [Cholera Toxin results in increased secretion of Water]; TAC1 protein inhibits the reaction [Cholera Toxin results in increased secretion of Water]
[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein] [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]
browse the term
